Chronic obstructive pulmonary disease (COPD) is a slow progressive disease characterized by chronic inflammation of the airways and airflow obstruction. COPD has a prevalence of 5--13% and is the fourth leading cause of death worldwide[@b1][@b2]. COPD is one of the most prevalent causes of death in North America and by 2020 it will be the third largest disease burden worldwide[@b3][@b4]. COPD mainly affects pulmonary function, but also affects nonrespiratory systems[@b5][@b6]. In addition, previous studies have reported muscle strength and exercise capacity deficits among patients with COPD resulting in impairment of postural control and balance function[@b7][@b8][@b9][@b10].

Hip fracture can lead to functional disability and high mortality rates in elderly people[@b11][@b12]. To regain function in independent daily living, nearly all patients with hip fracture require surgery and approximately 50% of patients regain previous mobility[@b13]. In addition, approximately 25% of patients receive long-term nursing home care despite independently performing daily activities before experiencing hip fracture[@b14][@b15]. The medical cost incurred because of hip fracture is high, and an economic burden of more than \$20 billion was estimated in 1997[@b16]. Ninety percent hip fractures are caused by falls[@b17], and fall injuries are common in patients with COPD[@b18]. A recent prospective observational study indicated that approximately one third of ambulatory patients with COPD had fall accidents during a 6-month follow-up period. We hypothesized that COPD is associated with hip fracture because fall injury rates are high among patients with COPD.

Falls in patients with COPD could have major complications, including mortality and morbidities such as hip fracture, potentially imposing an economic burden on health care services. Although previous studies have indicated a high fall incidence among patients with COPD, hip fracture risk has not been investigated extensively[@b19]. A large-scale population-based study analyzing COPD and hip fracture risk is lacking. Moreover, hip fracture prevention is a major public health concern, and identifying hip fracture risk factors is correlated to effective fall strategy establishment. Therefore, we conducted this retrospective population-based cohort study to investigate the hip fracture risk among patients with COPD.

Methods
=======

Study design and study population
---------------------------------

### Data source

A retrospective population-based cohort study was conducted using case--control matched analysis. Patient data were obtained from the Taiwan Longitudinal Health Insurance Database 2005 (LHID2005). The National Health Insurance program, established in Taiwan in March 1995, has over 25 million enrollees and covers more than 99% of the population of Taiwan. The LHID2005 contains data on 25.68 million claims from one million beneficiaries randomly sampled from the Registry for Beneficiaries of the National Health Insurance Research Database (NHIRD). The claims files contain information on ambulatory care; inpatient care; pharmacy use; date of service; International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes; and claimed medical expenses. The National Health Research Institutes manages the claims data and provides scrambled random identification numbers for insured patients to protect their privacy. For ethical reasons, the database provides de-identified secondary data. The data were analyzed anonymously and the requirement for informed consent was waived by institution of review board and this study is accordance to the guideline of STROBE (STrengthening the Reporting of OBservational studies in Epidemiology).

### Study patients

Patients with ambulatory care claims containing ICD-9-CM code 490--496 (COPD) between January 1, 2004 and December 31, 2007 were identified. To ensure that the COPD diagnoses were accurate, patients who received consistent diagnoses according to the ICD-9-CM at least 3 times in outpatient clinics or a primary diagnosis of COPD during hospitalization within 1 year were selected. Initially, 21,341 patients with COPD were enrolled. However, 4880 patients whose data were missing or were aged \<50 years and 222 patients with diagnoses of previously sustained hip fracture (ICD-9-CM code 820 and 821) were excluded. The study cohort comprised 16,239 patients with COPD, and the control cohort comprised 48,717 patients without COPD in a 1:3 ratio matched by age and sex in group level. And the patients with previous hip fracture were also excluded in control cohort. Each patient was monitored for 4 years, from the entry date to the diagnosis of hip fracture in an outpatient clinic, primary diagnosis during hospitalization, or the end of 2008.

### Baseline comorbidities and inhalation medication

Data on baseline variables, namely age, sex, hypertension (ICD-9-CM codes 401--405), hyperlipidemia (ICD-9-CM codes 272.0--272.4), stroke (ICD-9-CM codes 430--438), diabetes mellitus (DM; ICD-9-CM codes 250, 251), and autoimmune diseases (rheumatoid arthritis, RA; ICD-9-CM code 714.0; systemic lupus erythematous, SLE; ICD-9-CM code 710.0), were obtained for all patients. In addition, usage histories of nonsteroidal anti-inflammatory drugs (NSAIDs) and inhalation medications, such as ipratropium bromide administered using a metered-dose inhaler (MDI); fenoterol hydrobromide administered using an MDI, terbutaline sulfate administered using a Turbuhaler, or salbutamol sulfate administered using an MDI; tiotropium administered using a HandiHaler; formoterol administered using a Turbuhaler or salmeterol administered using an MDI; and formoterol/budesonide administered using a Turbuhaler or salmeterol/fluticasone administered using an MDI, were considered.

### Statistical analysis and 2-stage propensity score calibration

A Cox model was used to calculate an up to 4-year hip fracture hazard function and evaluate the hip fracture risk between the COPD and control cohorts, after adjustment for age, sex, DM, hypertension, hyperlipidemia, stroke, autoimmune diseases (RA, SLE), and inhaled medication and NSAID use.

To adjust for missing confounders, namely smoking, alcohol use, and body mass index (BMI), in the LHID cohort, a 2-stage approach was applied. In previous studies with 2-stage designs, the method for adjusting for missing confounders involved combining samples from the main data and validating data[@b18][@b19]. According to the inclusion criteria, we identified 350 patients with COPD in the main study (LHID cohort) and 1050 age- and sex-matched participants in the National Health Interview Survey 2005 (NHIS2005) conducted during 2004--2007 (comparison cohort). The comparison cohort had data on BMI, alcohol use, and smoking, which are crucial variables for patients with COPD that were lacking in the LHID cohort. Thus, a 2-stage propensity score matching method described by Stürmer *et al*. was employed to adjust for the missing high-dimensional confounders[@b20][@b21][@b22].

Let X denote an indicator variable for COPD. A value 1 is chosen for patients with COPD and 0 otherwise. Let X~c~ be a vector of observed confounders, namely patient age, sex, hypertension, stroke, hyperlipidemia, DM, autoimmune diseases, and inhaled medication and NSAID use. Let U denote an indicator for the missing confounders, smoking, alcohol use, and BMI. The propensity score is defined by the equation PS = Pr (X = 1\|X~c~), and the estimated PS and hip fracture association in a Cox proportional hazard model is defined as The propensity score is defined as the error-prone variable and is defined as the gold standard in the validation study. The measurement error model is, and the regression calibration after adjustment for X~c~ and U confounding factors estimator for the effect of X is [@b21]. The estimated is obtained after adjusting for missing confounders. Lin and Chen proposed TSC statistical methods. Unlike the aforementioned methods, the validity of the TSC method does not rely on a measurement error model[@b23]. We used the TSC method to estimate beta parameters and obtained results similar to those of the aforementioned process. Furthermore, hip fracture hazard curves based on time-to-event analysis (Kaplan--Meier method) for patients with COPD and the comparison cohort and hip fracture hazard curves stratified by inhaled medications usage for the COPD cohort were plotted. All data analyses were performed using the SAS statistical package (Version 9.4; SAS Institute, Cary, NC, USA). A *P* value of \<0.05 was considered statistically significant.

Results
=======

The COPD cohort in the LHID comprised 16,239 patients with COPD, and the control cohort comprised 48,717 patients without COPD. A total of 350 patients with COPD and 1050 comparison participants without COPD from the NHIS were included in the validation cohort. The demographic characteristics and comorbid medical disorders of these cohorts are shown in [Table 1](#t1){ref-type="table"}.

The incidence of hip fracture was 649 per 10,000 person-years and 369 per 10,000 person-years in the COPD and control cohorts, respectively. In patients with COPD, the crude hazard ratio (HR) for hip fracture occurrence was 1.78 (95% confidence interval \[CI\], 1.57--2.01, *P* \< 0.001). After adjustment for age, sex, hypertension, stroke, hyperlipidemia and DM, autoimmune diseases, and inhaled medication and NSAID use, the adjusted HR was 1.59 (95% CI, 1.38--1.82, *P* \< 0.001). After 2-stage propensity score calibration, the adjusted HR was 1.57 (95% CI, 1.36--1.81, *P* \< 0.001) ([Table 2](#t2){ref-type="table"}).

[Table 3](#t3){ref-type="table"} lists the incidence and hazard ratios for hip fracture in COPD patients with inhalation medication (N = 10,362) and without inhalation medication (N = 5,877) in comparison with the control cohort (N = 48,717). The incidence of hip fracture was 717 per 10,000 person-years in the COPD and inhaled medication cohort, whereas it was 595 per 10,000 person-years in the COPD without inhaled medication cohort. The crude HR of hip fracture occurrence for patients with COPD using inhaled medication was 2.04 (95% CI, 1.72--2.41, *P* \< 0.001), and the adjusted HR was 1.72 (95% CI, 1.45--2.04, *P* \< 0.001). The crude HR for patients with COPD not using inhaled medication was 1.63 (95% CI, 1.40--1.89, *P* \< 0.001), and the adjusted HR was 1.46 (95% CI, 1.25--1.69, *P* \< 0.001).

Kaplan--Meier hazard curves for hip fracture in the COPD and control cohorts over the 4-year follow-up period are shown in [Fig. 1](#f1){ref-type="fig"}. Log-rank test analysis revealed that the patients in the COPD cohort had higher risk (HR = 1.78, *P* \< 0.001) than those of the patients in the non-COPD cohort ([Fig. 1](#f1){ref-type="fig"}). Patients with COPD using inhaled medications had higher HRs (HR = 1.25, 95% CI 1.03--1.52, *P* = 0.027) for hip fracture than those of patients not using inhaled medication ([Fig. 2](#f2){ref-type="fig"}).

Discussion
==========

Our large-scale population-based study revealed that patients with COPD were at an increased risk of hip fracture after we controlled for other possible contributing factors. Previous studies have revealed that most hip fractures were caused by falls and that the prevalence of falls was high among patients with COPD[@b20]. Therefore, we hypothesized that patients with COPD are at a risk of hip fracture. The pathogenesis of hip fractures could be explained by fall mechanisms among patients with COPD.

A previous study indicated that muscle strength, balance, and gait pattern could be intrinsic factors contributing to falls[@b17][@b18][@b19]. Muscle strength reduction and balance impairment can be observed in patients with COPD[@b24]. Moreover, Butcher *et al*. observed that patients with COPD had gait deficits[@b9][@b10], which can be precipitating factors for hip fracture in patients with COPD. Adequate muscle strength and endurance are essential for maintaining postural stability and reducing postural sway[@b8]. Mathur *et al*. reported that patients with moderate to severe COPD had decreased muscle volume and strength and increased thigh intramuscular fat[@b25]. In addition to muscle strength, muscle endurance is affected by COPD. A case control study comparing the knee extensor muscle of patients with COPD and healthy participants indicated that patients with COPD showed compromised endurance and most of them could not complete the study protocol[@b26]. Patients with COPD had increased body sway during rest with difficulty in maintaining balance during motion of more than an arm distance[@b27]. Janssens *et al*. demonstrated that in patients with COPD, particularly those with inspiratory muscle weakness, postural instability was caused by decreased proprioception signal reliance on back muscles[@b8][@b28]. Furthermore, gait deficit is considered a contributing factor for falls in patients with COPD. Butcher *et al*. demonstrated that gait speed was lower in patients with COPD compared with healthy control participants in a 6-meter walking test[@b29]. In addition, a previous study noted a shorter walking distance in patients with COPD[@b8]. However, the direct correlation of gait speed and distance with falls remains uninvestigated. Moreover, kinematic variables of gait deficits, such as gait variability among patients with COPD, remain inadequately studied, and additional studies are warranted.

Nutrition deficit and muscle mass loss are common problems in patients with COPD[@b28]. Hip muscles prevent blunt injury in lateral side falls. Therefore, frail patients are less protected and more vulnerable to hip fracture[@b30]. Furthermore, vitamin D deficiency is associated with muscle weakness and postural instability, which increase the fall risk[@b31]. In addition, vitamin D deficiency is associated with secondary hyperparathyroidism, which stimulates bone resorption and increases the fracture risk[@b32]. A previous study showed that patients with COPD had low vitamin D levels[@b33]. Thus, nutrition deficit could be a factor contributing to the increased hip fracture risk among patients with COPD.

It is well established that smoking is an important risk factor for COPD and is associated with bone mineral density and increased fracture risk[@b34]. The adverse effect of smoking could explain the increased hip fracture risk for patients with COPD. Nicotine exposure reduces calcium absorption and influences bone modeling, resulting in low bone mineral density[@b35][@b36][@b37]. Therefore, smoking is a risk factor for both osteoporosis and COPD, and is a contributing factor for hip fracture among patients with COPD.

Corticosteroid use is a pathogenic factor for hip fractures among patients with COPD. It is estimated that more than 61.5% and 8.3% patients with COPD use inhaled medication and oral corticosteroids, respectively[@b38][@b39]. A cross-sectional study on patients with severe COPD treated with glucocorticoids with adequate calcium and vitamin levels revealed a 68% prevalence of osteoporosis and osteopenia[@b40]. A case control study with a large sample size revealed that patients with COPD using inhaled corticosteroids had a higher fracture risk than that of patients with COPD not using inhaled corticosteroids[@b41]. In addition, a systematic review and meta-analysis study revealed that a high dosage of inhaled corticosteroids is associated with an increased risk of fractures, including hip fractures, among patients with COPD. In addition to osteoporosis, respiratory and peripheral muscle weakness is caused by oral corticosteroids[@b42]. Long-term corticosteroid use may lead to muscle weakness, which is a pathogenic factor for hip fracture among patients with COPD. Furthermore, the study results revealed that patients with COPD using inhaled medication had a higher risk of experiencing hip fracture than that of patients not using the medication. Thus, steroids may play a crucial role in increasing the hip fracture risk among patients with COPD.

This study is the first to investigate COPD as a risk factor for hip fracture. Nevertheless, it is subject to several possible limitations. First, information on daily activities, smoking habits, body weight, and nutrition status is not recorded and quantified in the NHIRD. These factors are associated with the risk of hip fracture. Although smoking and malnutrition are common in patients with COPD, these confounders cannot be controlled completely in a large population-based study using the NHIRD. Therefore, we used a 2-stage propensity score calibration method and NHIS 2005 data for eliminating the confounding bias caused by smoking, alcohol use, and BMI. Second, COPD diagnosis and medical comorbidities were determined using ICD codes from the NHRID, and no information on the accuracy of these codes is available. To reduce the bias caused by the incorrect use of codes, we included patients who received 5 consecutive diagnoses of COPD in outpatient clinics or a primary diagnosis of osteoarthritis during hospitalization to ensure the validity of COPD diagnosis. Third, the influence of socioeconomic status on the risk of hip fracture was not presented in this study. Patients with higher socioeconomic status family generally had better medical resource and safer working environment than those families from lower socioeconomic status. COPD cohort could have lower socioeconomic status and lead them at higher risk of hip fracture. For considering this potential bias cuased by different socioeconomic status among COPD and non-COPD cohorts, we adjusted variable of income in further analysis and the data of adjusted HR was 1.60 (95% CI, 1.39--1.84, P \< 0.001), which did not change the outcome of this study. Finally, the COPD severity stage and detailed medication data were not recorded in the NHIRD and can influence the hip fracture risk. To eliminate these biases, we controlled for possible confounders such as age, steroid use, and comorbidities among the study and control cohorts. However the limitations of propensity score analyses cannot eliminate all confounding definitely and no detailed data of oral glucocorticoid and osteoporosis medication usage were mentioned in this study.

Conclusion
==========

This population-based retrospective cohort study revealed that patients with COPD were at a 1.57-times greater risk of sustaining hip fracture. Several factors contribute to hip fracture risk, such as falls, steroid use, muscle weakness, gait deficit, impaired balance, smoking, and nutrition deficit. We recommend implementing an appropriate hip fracture prevention strategy in the public health field by using a multidisciplinary approach to improve the quality of care for patients with COPD. Additional studies investigating the effect of hip fracture risk factors in patients with COPD are warranted.
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###### Demographic characteristics and comorbid medical disorders for subjects with COPD and in the comparison cohort in LHID main database and NHIS validation database, 2004--2007.

  **Variable**           **Main study**   **Validation study**                                       
  --------------------- ---------------- ---------------------- ------- ------ ------ ------- ------ -------
  Gender                                                                                             
   Male                      10538                64.9           31614   64.9   248    70.9    744    70.9
   Female                     5701                35.1           17103   35.1   102    29.1    306    29.1
  Age (years-old)                                                                                    
   51--60                     3058                18.8           9174    18.8    85    24.3    255    24.3
   61--70                     4019                24.7           12057   24.7    76    21.7    228    21.7
   \>70                       9162                56.4           27486   56.4   189    54.0    567    54.0
  Hypertension                                                                                       
   Yes                        8993                55.4           24032   49.3   220    62.9    549    52.3
   No                         7246                44.6           24685   50.7   130    37.1    501    47.7
  Hyperlipidemia                                                                                     
   Yes                        3591                22.1           10053   20.6    87    24.9    239    22.8
   No                        12648                77.9           38664   79.4   263    75.1    811    77.2
  Stroke                                                                                             
   Yes                        2419                14.9           5167    10.6    96    27.4    187    17.8
   No                        13820                85.1           43550   89.4   254    72.6    863    82.2
  Diabetes                                                                                           
   Yes                        3517                21.7           10428   21.4    96    27.4    218    20.8
   No                        12722                78.3           38289   78.6   254    72.6    832    79.2
  Autoimmune disease                                                                                 
   Yes                        577                 3.6            1194    2.5     12     3.4     37     3.5
   No                        15662                96.4           47523   97.5   338    96.6    1013   96.5
  Inhaled medications                                                                                
   Yes                        5877                36.2           1823    3.7    177    50.6     94     9.0
   No                        10362                63.8           46894   96.3   173    49.4    956    91.0
  Nsaid                                                                                              
   Yes                        4172                25.7           9264    19.0   191    54.6    540    51.4
   No                        12067                74.3           39453   81.0   159    45.4    510    48.6
  Smoking                                                                                            
   Yes                                                                          157    44.9    368    35.0
   No                                                                           193    55.1    682    65.0
  Drinking                                                                                           
   Yes                                                                           92    26.3    315    30.0
   No                                                                           258    73.7    735    70.0
  BMI (SD)                                                                      23.3   (3.7)   24.0   (3.7)

Abbreviation: COPD = chronic obstructive pulmonary disease.

###### The crude and adjusted hazard ratios for hip fracture among the sample subjects during the 4-years follow-up (N = 64956).

                                                                                  **Total sample N = 64956**   **Non-COPD N = 48717**   **COPD N = 16239**
  ------------------------------------------------------------------------------ ---------------------------- ------------------------ ---------------------
  Occurrence of hip fracture, N (%)                                                      1116 (1.7%)                 715 (1.5%)             401 (2.5%)
  Incidence per 100000 person-year (95% CI)                                             437 (435--439)             369 (367--371)         649 (644--654)
  Crude HR (95% CI)                                                                           --                        1.00            1.78\* (1.57--2.01)
  Adjusted HR (95% CI)[a](#t2-fn1){ref-type="fn"}                                             --                        1.00            1.59\* (1.38--1.82)
  propensity score calibration adjusted HR (95% CI)[b](#t2-fn2){ref-type="fn"}                --                        1.00            1.57\* (1.36--1.81)

^a^Adjustment for patient's age, sex, hypertension, stroke, hyperlipidemia and diabetes, Autoimmune and medications included Inhaled medications and Nsaid.

^b^Adjustment for patient's age, sex, hypertension, stroke, hyperlipidemia and diabetes, Autoimmune, Inhaled medications, Nsaid and missing confounders including smoking, drinking and body mass index. \**P* \< 0.001.

###### Incidence, crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for hip fracture during the 4-years Follow-up.

  **Presence of hip fracture**                       **Non-COPD N = 48717**                 **COPD Patients**                
  ------------------------------------------------- ------------------------ ----------------------------------------------- -----------------------------------------------
  follow-up period                                                                                                                                   
  Yes                                                         715                                  234                                             167
  Incidence per 100,000 person-years (95% CI)            369 (342--396)                      595 (519--671)                                  717 (606--828)
  Crude HR (95% CI)                                           1.00            1.63[\*](#t3-fn2){ref-type="fn"} (1.40--1.89)   2.04[\*](#t3-fn2){ref-type="fn"} (1.72--2.41)
  Adjusted HR[a](#t3-fn1){ref-type="fn"} (95% CI)             1.00            1.46[\*](#t3-fn2){ref-type="fn"} (1.25--1.69)   1.72[\*](#t3-fn2){ref-type="fn"} (1.45--2.04)

(*N* = 64956). Notes:

^a^Adjustments were made for age, sex, hypertension, stroke, hyperlipidemia and diabetes, Autoimmune and NSAID.

^\*^Indicates p \< 0.001.
